Sio Gene Therapies, Inc. (SIOX)
Market Closed
7 Feb, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
0. 48
+0.09
+22.627%
Pre Market
$
-0.04 -9.205% 0. 43
35.36M Market Cap
- P/E Ratio
1.74% Div Yield
7,588 Volume
- Eps
$ 0.39
Previous Close Want to track SIOX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
SIOX closed Wednesday higher at $0.48, an increase of 22.627% from Tuesday's close, completing a monthly increase of 0% or $0.48. Over the past 12 months, SIOX stock gained 0%.
SIOX is not paying dividends to its shareholders.
The last earnings report, released on Jun 11, 2024, missed the consensus estimates by -0.07%. On average, the company has fell short of earnings expectations by -0.05%, based on the last three reports.
Sio Gene Therapies, Inc. has completed 1 stock splits, with the recent split occurring on May 08, 2019.
The company's stock is traded on one exchange.
SIOX Chart
Sio Gene Therapies, Inc. (SIOX) FAQ
What is the stock price today?
The current price is $0.48.
On which exchange is it traded?
Sio Gene Therapies, Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is SIOX.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 1.74%.
What is its market cap?
As of today, the market cap is 35.36M.
Has Sio Gene Therapies, Inc. ever had a stock split?
Sio Gene Therapies, Inc. had 1 splits and the recent split was on May 08, 2019.
Sio Gene Therapies, Inc. Profile
| Biotechnology Industry | Healthcare Sector | David W. Nassif CEO | NASDAQ (NGS) Exchange | 829399104 CUSIP |
| US Country | 12 Employees | - Last Dividend | 8 May 2019 Last Split | - IPO Date |
Sio Gene Therapies Inc. is a biotechnology company in the clinical development phase, committed to pioneering gene therapies designed to fundamentally alter the prognosis for patients afflicted with neurodegenerative conditions. Its therapeutic pipeline is supported by strategic licensing agreements, including one with Oxford BioMedica (UK) Ltd. for the advancement and market introduction of AXO-Lenti-PD and associated gene therapy offerings. Furthermore, Sio Gene Therapies collaborates with The University of Massachusetts Medical School on the development and commercialization of other gene therapy candidates, notably AXO-AAV-GM1 and AXO-AAV-GM. Incorporated in 2014 and headquartered in New York, New York, the entity was known as Axovant Gene Therapies Ltd. prior to its renaming in November 2020.
Contact Information
Address: 130 West 42nd Street
Phone: 877 746 4891
Website: https://www.siogtx.com
